Analysis of 5-FU resistance in colon cancer using BH3 profiling
| Project/Area Number |
17K07200
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Tumor diagnostics
|
|---|
| Research Institution | Health Sciences University of Hokkaido (2018-2019)
Sapporo Medical University (2017) |
|---|
Principal Investigator |
KAWANO Yutaka 北海道医療大学, 予防医療科学センター, 准教授 (80398320)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
加藤 淳二 札幌医科大学, 医学部, 教授 (20244345)
平川 昌宏 札幌医科大学, 医学部, 助教 (50561023)
石川 和真 札幌医科大学, 医学部, 研究員 (30722417)
|
|---|
| Project Period (FY) |
2017-04-01 – 2020-03-31
|
| Project Status |
Completed (Fiscal Year 2019)
|
| Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2019: ¥780,000 (Direct Cost: ¥600,000、Indirect Cost: ¥180,000)
Fiscal Year 2018: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2017: ¥2,600,000 (Direct Cost: ¥2,000,000、Indirect Cost: ¥600,000)
|
|---|
| Keywords | 抗癌剤感受性 / 大腸癌 / BH3プロファイリング / 大腸癌細胞株 / 5-FU耐性 / BCLXL蛋白 / 抗がん剤感受性 |
|---|
| Outline of Final Research Achievements |
BH3 profiling identified BCLXL protein as a functional role for 5-FU resistance in colon cancer cell lines. Knockdown of BCLXL protein recovered the sensitivity to 5-FU in 5-FU resistant colon cancer cells. Furthermore, mice study showed that BCLXL inhibitor could both control tumor growth and cause apoptosis in 5-FU resistant colon cancer cells. In summary, BCLXL inhibitor is thought to be one of the promising drug for 5-FU resistant colon cancer.
|
| Academic Significance and Societal Importance of the Research Achievements |
BH3プロファイリングという新しい解析手法により、今までの方法では分からなかった抗がん剤の耐性メカニズムを明らかにした。このメカニズムを標的とした薬剤を使えば、大腸がんを効果的に殺すことが可能となり、さらに以前から使っていた抗がん剤も再び効くようになることが分かった。
|
Report
(4 results)
Research Products
(1 results)
